| Univariable analysis | Multivariable analysisa | ||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Age, per 1 year increment | 0.99 (0.95–1.03) | 0.836 | 1.02 (0.97–1.08) | 0.388 |
Female | 1.44 (0.72–2.88) | 0.396 | 1.28 (0.63–2.62) | 0.492 |
Any cranial symptoms at baseline | 0.50 (0.26–0.95) | 0.034 | 0.83 (0.40–1.72) | 0.622 |
Polymyalgia rheumatica at baseline | 1.13 (0.61–2.09) | 0.699 | 1.30 (0.63–2.62) | 0.492 |
LVLs at baseline | 3.20 (1.53–6.72) | 0.002 | 3.54 (1.52–8.24) | 0.003 |
 Any lesions of the aortic branchesb | 1.44 (0.78–2.66) | 0.240 |  |  |
 Any lesions of the aortac | 2.07 (1.12–3.82) | 0.02 |  |  |
 Any structural vascular damaged | 1.73 (0.90–3.35) | 0.102 |  |  |
 Aneurysm of the aorta | 2.76 (0.98–7.78) | 0.054 |  |  |
CRP at baseline per 1 mg/dl increment | 1.00 (0.95–1.05) | 0.930 |  |  |
Initial dose of PSL per 0.1 mg/kg/day increment | 1.01 (0.88–1.17) | 0.874 |  |  |
Dose of PSL at week 4 per 0.1 mg/kg/day increment | 1.04 (0.86–1.25) | 0.685 |  |  |
Dose of PSL at week 8 per 0.1 mg/kg/day increment | 1.03 (0.83–1.29) | 0.785 |  |  |
Dose of PSL at week 12 per 0.1 mg/kg/day increment | 1.13 (0.87–1.46) | 0.356 |  |  |
Immunosuppressive drug use at baseline | 1.54 (0.65–3.67) | 0.330 |  |  |